Whalesbook
📉 Numbers ka Funda
Ab numbers ki baat karein toh, company ki consolidated net revenues 7.9% YoY badhkar ₹434.3 crore ho gayi, haan, QoQ thodi 7.9% neeche thi. Standalone net revenues 6.8% YoY badhkar ₹389.6 crore hui, par QoQ 9% kam thi. Asli dhamaka toh consolidated EBITDA mein hai, jo 162.5% YoY jump karke ₹31.5 crore par pahuncha. Isse consolidated EBITDA margin 7.3% par aa gaya, pichhle saal yeh sirf 3.0% tha. Standalone EBITDA bhi 28.9% badhkar ₹25.9 crore raha, aur margins bhi 5.5% se 6.6% ho gaye.
🚀 Growth Kahan Se Aayi?
Yeh 162.5% ka EBITDA growth impressive hai, kyunki isme ₹29 crore ka one-off cost bhi shamil tha (remediation, penalties, tech transfers ka kharcha). Is growth ka sabse bada hero raha international formulation business, jo 26.2% YoY badhkar ₹1,356 crore ho gaya. Ismein regulatory markets se 25.9% ki growth, US se 21.6%, Europe se 36.9%, aur emerging markets se 26.8% ki growth aayi. API business bhi 24% YoY badhkar ₹344 crore tak pahuncha, aur Patalganga site ko USFDA se EIR mil gaya bina kisi 483 observations ke, jo ki bohot badi baat hai. Warren Remedies wala OTC business toh 43% se bhi zyada bhaga.
🔮 Future Plans & Challenges
Management ka kehna hai ki Europe market mein 20% se zyada growth ka potential hai aur margins bhi sudhrenge. Unka target hai FY28-29 tak Europe se ₹400-500 crore ka revenue earn karne ka. US market mein bhi commercial sales aur margin improvement ki umeed hai, haalanki Goa Plant II mein US FDA ke issues hain. API business ke liye FY27 consolidation ka saal rahega, jisme Auric site ka US FDA/EU qualification margins ko aur boost karega.
Ab ek chiz jo thodi down hai, woh hai domestic formulation business ka flat rehna, khaaskar acute therapies mein. Par achi khabar ye hai ki MAT basis par prescription rankings sudhar rahe hain.
🚩 Risks & Outlook
Sabse badi chinta company par ₹900 crore ka debt hai. Management ne plan banaya hai ki ise March 2027 tak ₹775-800 crore tak kam karenge, cash generation aur controlled capex (saal mein ₹35-40 crore maintenance capex) se. Investors is debt reduction plan ko closely follow karenge. Goa Plant II par US FDA ke jo bhi challenges hain, unpar bhi nazar rakhni hogi. Domestic market mein jo pressure hai, usko kaise overcome karte hain, ye bhi dekhna hoga.
Overall, international segments mein sustained growth, Europe ka vision, Auric site ka qualification yeh sab positive hain. Par debt management aur domestic performance peafi important factors rahenge aane wale samay mein.